Skip to content

Batch information on every product pageTHC < 0.3%Shipped from France10% off when you sign up

4-O-methylhonokiol

A magnolia neolignan, a preferential partial CB2 agonist and a substrate-selective COX-2 inhibitor.

Level of detail

C₁₉H₂₀O₂

CAS 68592-15-4

Family
PhytocannabinoidOutside cannabis
Origin
A plant other than hemp
Molar mass
280.37 g/mol

Updated on

In plain terms

4-O-Methylhonokiol comes from magnolia. It binds to the CB2 receptor, mainly associated with immune cells, about ten times better than to the brain's CB1 receptor. In mice, it also increased the amount in the brain of a cannabinoid the body makes itself, 2-AG.

Receptors and activity

Target network

CB2Partial agonistKi = 189 nM · human[3H]CP55,940 displacement, hCB2 membranes; partial agonist in [35S]GTPγS (EC50 = 286 nM) and β-arrestin, full on cAMP; other Ki: < 50 nM (Schuehly 2011), 290 nM (Pandey 2023)
  • Activates
  • Blocks or inhibits
  • Binds or modulates

The lower the cited value, the closer the target sits to 4-O-methylhonokiol: one ring per factor of 100. A target with no measured value stays on the edge.

Where these targets live

Where each target has been found in humans, according to the cited studies. The map shows the target, not an effect of 4-O-methylhonokiol.

Brain, side view
Body, front view
Blood

CB2CB2 found in 5 regions of the body

  1. SpleendenseHighly abundant in the spleen1
  2. Immune cellspresentMainly B cells and natural killer cells1
  3. SkinpresentKeratinocytes, mast cells and nerve fibres2
  4. GutpresentImmune cells of the colonic mucosa3
  5. BonepresentPresent on osteoclasts4

Cited values

  1. CB2Partial agonistKi = 189 nM · human45 out of 100

    Chicca et al. 2015, J Neuroinflammation (new tab) · [3H]CP55,940 displacement, hCB2 membranes; partial agonist in [35S]GTPγS (EC50 = 286 nM) and β-arrestin, full on cAMP; other Ki: < 50 nM (Schuehly 2011), 290 nM (Pandey 2023)

  2. CB1ModulatorKi = 2.4 µM · human27 out of 100

    Chicca et al. 2015, J Neuroinflammation (new tab) · [3H]CP55,940 displacement, hCB1 membranes; functional activity not described; Ki of 3.85 µM according to Pandey 2023

  3. COX-2 (2-AG oxygenation)InhibitorIC50 = 301 nM · mouse42 out of 100

    Chicca et al. 2015, J Neuroinflammation (new tab) · PGE2-glycerol ester formation, RAW264.7 cells; IC50 of 1.21 µM for PGE2 formation (substrate-selective inhibition)

Bar length follows the measured value (Ki, Kd, EC50 or IC50), on one scale shared by every entry, from 100 µM to 0.1 nM. A target with no cited value has no bar.

Measured effects

Not characterised. No placebo-controlled human trial has measured the effects of 4-O-methylhonokiol, so no level is shown.

Levels computed from placebo-controlled human trials: difference from placebo on 100, at the dose and route stated. Read the method

Pharmacology

4-O-Methylhonokiol is one of the clearest examples of a cannabinoid ligand from a plant unrelated to cannabis. In 2011, Schuehly and colleagues described it as a selective CB2 ligand (Ki below 50 nM) with an unusual functional profile: inverse agonism on the Gi pathway together with a strong CB2-dependent rise in intracellular calcium; using derivatives, they showed that CB2-dependent cyclic AMP formation, not calcium, is involved in osteoclast formation. In 2015, Chicca and colleagues measured a Ki of 188.5 nM at human CB2 versus 2.4 µM at CB1 and characterised it as a CB2 agonist, partial in [35S]GTPγS binding and β-arrestin recruitment, full on cAMP. They also described a second mode of action: the molecule substrate-selectively inhibits COX-2 oxygenation of 2-AG (IC50 = 301 nM, versus 1.21 µM for PGE2 formation), and raised mouse brain 2-AG dose-dependently between 3 and 20 mg/kg, with brain concentrations of 200 to 300 nM about 7 h after intraperitoneal injection. It was isolated in 2023 from Magnolia grandiflora seeds with a Ki of 0.29 µM at CB2 and 3.85 µM at CB1 (Pandey 2023). Labelled with carbon-11, it has been studied as a radiotracer in rats, where it also proved to be a P-glycoprotein substrate (Lin 2025). No human data exist.

History

Source
A neolignan of the genus Magnolia: it was isolated, together with magnolol and honokiol, from the seeds of Magnolia grandiflora by fractionation guided by cannabinoid receptor binding (Pandey 2023). It does not come from cannabis.

Biosynthetic pathway

A biphenyl neolignan, the 4'-O-methylated derivative of honokiol. The enzymes of its biosynthesis in magnolias were not described in the sources consulted. Its structure has no kinship with the terpenophenolic skeleton of cannabis cannabinoids.

Classification

Family, origin and source verification

Family

Phytocannabinoid › Outside cannabis

Presence in the plant

Made by an organism other than cannabis

Chemistry

Biphenyl neolignan

Verification

Every fact on this entry was checked against its primary sources on 20 October 2026.

Wikipedia (English)

4-O-Methylhonokiol (new tab)

Article paired by the molecule's structure (InChIKey), revision read on 19 October 2026. Read as a second opinion, never cited as a source.

References

Identifiers

Names

IUPAC name
2-(4-methoxy-3-prop-2-enylphenyl)-4-prop-2-enylphenol
Other names
4-methoxyhonokiol · MH

Identifiers

Formula
C₁₉H₂₀O₂
CAS
68592-15-4
PubChem CID
155160(new tab)
InChIKey
OQFHJKZVOALSPV-UHFFFAOYSA-N
SMILES
COC1=C(C=C(C=C1)C2=C(C=CC(=C2)CC=C)O)CC=C

Machine-readable entry (JSON)

LLM ingestion format: a structured superset of the entry (identifiers, binding, versioned legal status). Full corpus.